Sanuscode Wart Corn Remover

Uses and Indications

This drug is indicated for the removal of warts and corns.

There are no teratogenic effects associated with this drug. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

The affected area should be washed thoroughly. Soaking the wart in warm water for 5 minutes is optional but may enhance the effectiveness of the treatment. After washing, the area must be dried completely.

If necessary, the medicated plaster can be cut to fit the size of the wart. The plaster should then be applied directly to the wart.

This application should be repeated every 48 hours as needed, with a maximum treatment duration of up to 12 weeks.

Contraindications

Use is contraindicated on irritated, infected, or reddened skin due to the potential for exacerbating the condition. Application is also contraindicated on genital warts, facial warts, moles, birthmarks, or warts with hair growing from them, as these areas may be sensitive and could lead to adverse reactions. Additionally, the product should not be applied to mucous membranes, given the risk of irritation and other complications.

Warnings and Precautions

For external use only. Healthcare professionals should advise patients to avoid ingestion of the product. In the event of accidental swallowing, immediate medical assistance should be sought, or the patient should contact a Poison Control Center without delay.

Patients with diabetes or those experiencing poor blood circulation are advised to consult a healthcare provider prior to use. It is essential to monitor any symptoms that may arise during treatment.

If discomfort persists or worsens, patients should discontinue use and seek medical advice promptly.

Side Effects

For external use only. Patients are advised to stop use and consult a doctor if discomfort persists or worsens. Additionally, individuals with diabetes or poor blood circulation should seek medical advice before using this product.

Drug Interactions

No drug interactions have been identified for this medication. Additionally, there are no interactions noted between this drug and laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Sanuscode Wart Corn Remover (salicylic acid 40% wart corn remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy.

Pregnancy

Pregnant patients should avoid using this product on irritated, infected, or reddened skin, as well as on genital warts or warts located on the face. Additionally, it should not be applied to moles, birthmarks, or warts with hair growing from them, nor on mucous membranes.

Women of childbearing potential are advised to consult a healthcare professional if they have diabetes or poor blood circulation prior to using this product. The potential risks associated with use during pregnancy have not been fully established, and caution is recommended to ensure the safety of both the mother and the fetus.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or any lactation considerations. Healthcare professionals should exercise caution and consider the potential risks and benefits when prescribing this medication to lactating mothers. Further research may be necessary to fully understand the implications for breastfed infants.

Renal Impairment

There is no specific information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in these patients to ensure safety and efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted in these patients to ensure safety and therapeutic effectiveness.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved and the individual patient's response. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and if the ingestion was recent.

Furthermore, specific antidotes or treatments may be indicated based on the substance involved in the overdose. Consultation with a poison control center or a medical toxicologist is recommended to guide the management of the patient and to determine the most appropriate interventions.

Overall, vigilance and prompt action are crucial in managing cases of suspected overdose, even in the absence of detailed information regarding specific overdosage effects.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the insert.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. It is important to inform patients that the product should not be applied to irritated, infected, or reddened skin, as well as on genital warts, warts on the face, moles, birthmarks, or warts with hair growing from them, and on mucous membranes.

Patients should be instructed to discontinue use and consult a doctor if discomfort persists or worsens. Additionally, healthcare providers should emphasize the importance of avoiding contact with the eyes or face, and if the product inadvertently gets into the eyes, patients should rinse thoroughly with water.

Furthermore, patients with diabetes or poor blood circulation should be encouraged to consult a doctor before using the product to ensure safety and appropriateness.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product within the temperature range of 59°F to 86°F (15°C to 30°C) to maintain its efficacy and integrity. Proper storage conditions should be observed to ensure optimal performance.

Additional Clinical Information

Patients should repeat the administration every 48 hours as needed, for a maximum duration of 12 weeks. Clinicians are advised to counsel patients to consult a doctor if they have diabetes or poor blood circulation. In the event of accidental ingestion, patients should seek medical assistance or contact a Poison Control Center immediately.

Drug Information (PDF)

This file contains official product information for Sanuscode Wart Corn Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)